|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hair as a biological specimen for therapeutic drug monitoring显示文摘 | Beumer JH Bosman IJ Maes RA | 2001 | International Journal of Clinical Practice2001，55，6： | 1 |
| 2 | In vitro eytotoxieity, pharmacokinetics, tissue distribution, and metabolism of small- molecule protein kinase D inhibitors, kb-NB142-70 and kb- NB165-09, in mice bearing human cancer xenografts显示文摘 | Guo J Clansen DM Beumer JH | 2013 | Cancer Chemother Pharmacol2013，71，2： | 1 |
| 3 | Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype 显示文摘 | Beumer JH Buckle T Ouwehand M | 2007 | Invest New Drugs2007，25，： | 1 |
| 4 | Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma:a phaseⅠ/Ⅱstudy and pharmacokinetic analysis显示文摘 | Tawbi HA Beumer JH Tarhini AA | 2013 | Ann Oncol2013，24，4： | 1 |
| 5 | Phase Ⅰ pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase in- hibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma显示文摘 | Reardon DA Egorin M J Desjardins A Vredenburgh J J Beumer JH Lagattuta TF | 2009 | Cancer2009，115，10： | 1 |
| 6 | Safety and effi- cacy of decitabine in combination with temozolomide in metastatic melanoma: A phase Ⅰ/ Ⅱ study and pharma- cokinetic analysis显示文摘 | Tawbi HA Beumer JH Tarhini AA | 2013 | Ann Oncol2013，24，4： | 1 |
| 7 | Role of PARP inhibi- tors in cancer biology and therapy 显示文摘 | Davar D Beumer JH Hamieh L etal | 2012 | Curr Med Chem2012，19，23： | 1 |
| 8 | A mass balance and disposition study of the DNA methyhransferase inhibitor ze- bularine (NSC 309132) and three of its metabolites in mice 显示文摘 | BEUMER JH JOSEPH E EGORIN MJ | 2006 | Clin Cancer Res2006，12，19： | 1 |
| 9 | Concentra- tions of the DNA methyltransferase inhibitor 5-fluoro-2'- deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouri- dine (THU) 显示文摘 | Beumer JH Parise RA Newman EM | 2008 | Cancer Chemother Pharmacol2008，62，2： | 1 |
| 10 | Evaluation of human plasma protein binding of trabeetedin(Yondelis,ET-743)显示文摘 | Beumer JH Lopez-Lazaro L ScheJlens JH | 2009 | Curr Clin Pharmacol2009，4，1： | 1 |
| 11 | Role of PARP inhibitors in cancer biology and therapy显示文摘 | Davar D Beumer JH Hamieh L | | 0，，23： | 1 |
| 12 | A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor,vorinostat(suberoylanilide hydroxamicacid,SAHA),and its metabolites in human serum显示文摘 | Parise RA Holleran JL Beumer JH | 2006 | J Chromatogr B2006，840，2： | 1 |
| 13 | Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma:a phaseⅠ/Ⅱstudy and pharmacokinetic analysis显示文摘 | Tawbi HA Beumer JH Tarhini AA | 2013 | Ann Oncol2013，24，4： | 1 |
| 14 | A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor,vorinostat (suberoylanilide hydroxamicacid,SAHA),and its metabolites in human serum显示文摘 | Parise RA Holleran JL Beumer JH | 2006 | J Chromatogr B Analyt Technol Biomed Life Sci2006，840，2： | 1 |
| 15 | Mass balance studies,with a focus on anticancer drugs显示文摘 | Beumer JH Beijnen JH Schellens JH | 2006 | Clin Pharmacokinet2006，45，1： | 1 |
| 16 | Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype 显示文摘 | Beumer JH Buckle T Ouwehand M | 2007 | Invest New Drugs2007，25，1： | 1 |
| 17 | Body-surface area-based chemo- therapy dosing:appropriate in the 21st century? 显示文摘 | Beumer JH Chu E Salamone SJ | 2012 | J Clin Oncol2012，30，31： | 1 |
| 18 | A liquid ehromatography-eleetrospray ionization tandem mass spectro- metric assay for quantitation of the histone deaeetylase inhibitor, vorinostat ( suberoylanilide hydroxamieaeid, SAHA ) , and its metabolites in human serum显示文摘 | PARISE RA HOLLERAN JL BEUMER JH | 2006 | J Chromatogr B2006，840，2： | 1 |
| 19 | Plas- ma pharmacokinetics and oral hioavailahility of the 3, 4, 5, 6-tetrahydrouridine (THU) prodrug, tri acetyl-THU(taTHU), in mice 显示文摘 | Beumer JH Eisesman JL Gilbert JA | 2011 | Cancer Che- mother Pharmacol2011，67，2： | 1 |
| 20 | Therapeutic drug monitoring of 5-flu- orouracil显示文摘 | Lee J J Beumer JH Chu E | 2016 | Cancer Chemother Pharmaco12016，20，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员